TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia

Summary, in English

TP53 mutations in the absence of 17p-deletion correlate with rapid disease progression and poor survival in chronic lymphocytic leukemia (CLL). Herein, we determined the TP53 mutation frequency in 268 newly diagnosed CLL patients from a population-based material. Overall, we detected TP53 mutations in 3.7% of patients (n = 10), where 7/10 cases showed a concomitant 17p-deletion, confirming the high prevalence of TP53 mutation in 17p-deleted patients. Only 3 (1.1%) of the newly diagnosed patients in our cohort thereby carried TP53 mutations without 17p-deletion, a frequency that is much lower than previous reports on referral cohorts (3-6%). Our findings imply that TP53 mutations are rare at CLL onset and instead may arise during disease progression. (C) 2010 Elsevier Ltd. All rights reserved.

• Author: Norafiza Zainuddin; Fiona Murray; Meena Kanduri; Rebeqa Gunnarsson; Karin E. Smedby; Gunilla Enblad; Jesper Jurlander; Gunnar Juliusson; Richard Rosenquist
• Department/s: Stem Cell Center; StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
• Publishing year: 2011
• Language: English
• Pages: 272-274
• Publication/Series: Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
• Volume: 35
• Issue: 2
• Full text: - 1 MB; Download statistics
• Links: http://dx.doi.org/10.1016/j.leukres.2010.08.023
• Document type: Journal article
• Publisher: Elsevier
• Topic: Cancer and Oncology
• Keywords: TP53 mutation; 17p-deletion; Prognosis; Chronic lymphocytic leukemia
• Status: Published
• ISBN/ISSN/Other: ISSN: 1873-5835